论文部分内容阅读
肿瘤的生长和转移与肿瘤区的血管密切相关。1971年Folkman首先提出抑制肿瘤血管形成可作为肿瘤治疗的一个途径,随后这种以肿瘤血管为靶的治疗策略——肿瘤血管靶向治疗(toumor vascular targeting therapy)日益受到重视。血管内皮生长因子(vascular endothelial growth factor,VEGF)是最重要的血管形成因子之一,VEGF及其受体(VEGFR)是肿瘤血管靶向治疗的理想靶点。以VEGF为靶点的治疗实验已有大量报道,以VEGFR为靶点近期亦有较成功的尝试,本实验旨在观察和比较大肠癌组织中VEGF及其受体KDR的表达差异,为确定以VEGF及VEGFR作为肿瘤血管靶向治疗的靶点何者为优提供依据。
The growth and metastasis of tumors are closely related to the blood vessels in the tumor area. In 1971, Folkman first proposed that inhibiting tumor angiogenesis can be used as a therapeutic approach for tumors. Subsequently, this tumor blood vessel-targeted treatment strategy, toumor vascular targeting therapy, has received increasing attention. Vascular endothelial growth factor (VEGF) is one of the most important angiogenic factors. VEGF and its receptor (VEGFR) are ideal targets for tumor vascular targeted therapy. Therapeutic experiments targeting VEGF have been widely reported. Recent attempts to target VEGFR have also been successfully tried. This experiment aims to observe and compare the expression differences of VEGF and its receptor KDR in colorectal cancer tissues. VEGF and VEGFR are the targets for tumor vascular targeted therapy and provide the basis for excellence.